Recent Pfizer Press Releases

  • 9/19/14 8:00 am EDT
    • Efforts in support of the United Nations Millennium Development Goal (MDG) 4 to reduce under-5 child mortality rate.
    • Programs designed to reach children in remote locations in five African countries.
    NEW YORK--(BUSINESS WIRE)--The Pfizer Foundation today announced $2 million in grant funding for pilot programs to improve immunization coverage in Africa. The programs will focus on ‘last-mile’ interventions to reach underserved populations living in Ethiopia, Malawi, Rwanda, Uganda and Zambia. Grant recipients include UNICEF, Save the Children and International Rescue Committee. The grants will focus on building the capacity of health caremore...
  • 9/3/14 10:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Geno Germano, Group President, Global Innovative Pharma Business, at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2014 at 12:55 p.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Morgan Stanley Global Healthcare Conference” link in the For Investorsmore...
  • 8/28/14 1:15 pm EDT
    NEW YORK & CARMIEL, Israel--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Geno Germano, Group President, Global Innovative Pharma Business, at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2014 at 12:55 p.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Morgan Stanley Global Healthcare Conference” link in the For Investorsmore...
  • 8/28/14 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s investigational Clostridium difficile (C. difficile) vaccine candidate (PF-06425090). Currently in Phase 2 clinical development, the vaccine candidate is designed to prevent C. difficile-associated disease, which can include life-threatening diarrhea and pseudomembranous colitis. “C.more...
  • 8/26/14 8:00 am EDT

    Agreement to Combine Merck’s Investigational Anti-PD-1 Antibody Pembrolizumab and Pfizer’s Crizotinib (XALKORI®) in Clinical Trial

    NEW YORK & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s investigational Clostridium difficile (C. difficile) vaccine candidate (PF-06425090). Currently in Phase 2 clinical development, the vaccine candidate is designed to prevent C. difficile-associated disease, which can include life-threatening diarrhea and pseudomembranous colitis. “C.more...
  • 8/21/14 1:31 pm EDT
    • Eliquis demonstrated noninferiority in the primary efficacy endpoint of recurrent symptomatic venous thromboembolism (VTE) or VTE-related death versus enoxaparin/warfarin in the AMPLIFY trial
    • Eliquis demonstrated superiority in the primary safety endpoint of major bleeding versus enoxaparin/warfarin in the AMPLIFY trial
    PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s investigational Clostridium difficile (C. difficile) vaccine candidate (PF-06425090). Currently in Phase 2 clinical development, the vaccine candidate is designed to prevent C. difficile-associated disease, which can include life-threatening diarrhea and pseudomembranous colitis. “C.more...
  • 8/21/14 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that the company has initiated a multi-center, open-label expanded access program (EAP) in the United States for the investigational CDK 4/6 inhibitor, palbociclib. Through the program, palbociclib is being made available for use in combination with letrozole for post-menopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer for whommore...
  • 8/20/14 8:00 am EDT
    • Fourteen abstracts to be presented, including new analyses from the ARISTOTLE®, AMPLIFY® and AMPLIFY-EXT trials evaluating patients with nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE)
    • New global health economics and outcomes research (GHEOR) assessing Eliquis cost effectiveness and real-world comparative effectiveness research will also be presented
    PRINCETON, N.J. and NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) announced today that they will present 14 abstracts (oral and poster presentations) at the ESC Congress 2014, organized by the European Society of Cardiology, to be held August 30 to September 4 in Barcelona, Spain. The new clinical trial data and GHEOR analyses assessing cost effectiveness and real-world use reinforce the alliance’s commitment to the ongoing analysis ofmore...
  • 8/18/14 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced it has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for palbociclib. This NDA requests FDA approval of palbociclib, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who have not received previous systemicmore...
  • 8/14/14 5:01 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bivalent recombinant LP2086 (rLP2086), the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 through 25 year olds. The FDA has also granted Priority Review designation for the BLA, providing an anticipatedmore...